- Home
- PYPD vs LGCL Comparison
PYPD vs LGCL Comparison
Compare PYPD & LGCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- LGCL
- Stock Information
- Founded
- PYPD 2008
- LGCL 2009
- Country
- PYPD Israel
- LGCL China
- Employees
- PYPD N/A
- LGCL N/A
- Industry
- PYPD Medical/Dental Instruments
- LGCL
- Sector
- PYPD Health Care
- LGCL
- Exchange
- PYPD Nasdaq
- LGCL NYSE
- Market Cap
- PYPD 26.7M
- LGCL 29.8M
- IPO Year
- PYPD 2020
- LGCL 2024
- Fundamental
- Price
- PYPD $2.90
- LGCL $0.46
- Analyst Decision
- PYPD Strong Buy
- LGCL
- Analyst Count
- PYPD 2
- LGCL 0
- Target Price
- PYPD $10.50
- LGCL N/A
- AVG Volume (30 Days)
- PYPD 19.1K
- LGCL 93.1K
- Earning Date
- PYPD 05-14-2025
- LGCL 11-22-2024
- Dividend Yield
- PYPD N/A
- LGCL N/A
- EPS Growth
- PYPD N/A
- LGCL N/A
- EPS
- PYPD N/A
- LGCL 0.07
- Revenue
- PYPD N/A
- LGCL $145,690,427.00
- Revenue This Year
- PYPD N/A
- LGCL N/A
- Revenue Next Year
- PYPD N/A
- LGCL N/A
- P/E Ratio
- PYPD N/A
- LGCL $6.98
- Revenue Growth
- PYPD N/A
- LGCL N/A
- 52 Week Low
- PYPD $2.30
- LGCL $0.28
- 52 Week High
- PYPD $4.75
- LGCL $3.76
- Technical
- Relative Strength Index (RSI)
- PYPD 56.83
- LGCL N/A
- Support Level
- PYPD $2.71
- LGCL N/A
- Resistance Level
- PYPD $2.89
- LGCL N/A
- Average True Range (ATR)
- PYPD 0.19
- LGCL 0.00
- MACD
- PYPD 0.02
- LGCL 0.00
- Stochastic Oscillator
- PYPD 56.25
- LGCL 0.00
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.